EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioXcel Therapeutics's enterprise value is $114.75 Mil.
BioXcel Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-165.42 Mil. Therefore, BioXcel Therapeutics's EV-to-EBITDA for today is -0.69.
The historical rank and industry rank for BioXcel Therapeutics's EV-to-EBITDA or its related term are showing as below:
BTAI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.28 Med: -1.18 Max: -0.23
Current: -0.69
During the past 8 years, the highest EV-to-EBITDA of BioXcel Therapeutics was -0.23. The lowest was -5.28. And the median was -1.18.
BTAI's EV-to-EBITDA is ranked worse than 100% of 462
companies
in the Biotechnology industry
Industry Median: 9.55
vs BTAI: -0.69
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
BioXcel Therapeutics EV-to-EBITDA Historical Data
The historical data trend for BioXcel Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioXcel Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, BioXcel Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's EV-to-EBITDA falls into.
BioXcel Therapeutics's current Enterprise Value is $114.75 Mil.
BioXcel Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-165.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
BioXcel Therapeutics's PE Ratio for today is calculated as:
BioXcel Therapeutics's share price for today is $2.57.
BioXcel Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of BioXcel Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
BioXcel Therapeutics (BioXcel Therapeutics) Business Description
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BTAI has been successfully added to your 